Kennedy Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kennedy Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Buy	3,503 +288	+9%	+$98K	0.02%	474
2025 Q4	$1.28M	Sell	3,215 -5	-0.2%	-$2.21K	0.03%	460
2025 Q3	$1.47M	Buy	3,220 +1,552	+93%	+$632K	0.03%	475
2025 Q2	$544K	Buy	1,668 +127	+8%	+$35.1K	0.01%	542
2025 Q1	$416K	Buy	1,541 +6	+0.4%	+$1.54K	0.01%	591
2024 Q4	$361K	Sell	1,535 -944	-38%	-$248K	0.01%	645
2024 Q3	$682K	Buy	2,479 +301	+14%	+$78.4K	0.02%	624
2024 Q2	$529K	Buy	2,178 +630	+41%	+$99.5K	0.01%	636
2024 Q1	$231K	Buy	+1,548	New	+$258K	﹤0.01%	693
2021 Q2	–	Sell	-1,442	Closed	-$204K	–	627
2021 Q1	$204K	Buy	+1,442	New	+$217K	﹤0.01%	647

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's ALNY Position: Q1 2026 in Review

Kennedy Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 9% in Q1 2026, buying an estimated $98K and bringing the position to 3,503 shares worth $1.16M. The position accounts for 0.02% of the portfolio, ranked #474.

Kennedy Capital Management first reported a position in ALNY in Q1 2021 and has held it in 10 quarters since. The position peaked at $1.47M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Kennedy Capital Management held 3,503 shares of Alnylam Pharmaceuticals worth $1.16M as of Q1 2026.
Kennedy Capital Management bought 288 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $98K.
Alnylam Pharmaceuticals made up 0.02% of Kennedy Capital Management's portfolio in Q1 2026, its #474 holding.
Kennedy Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
Kennedy Capital Management's Alnylam Pharmaceuticals position peaked at $1.47M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.